So far, 2024 has been a roller coaster for the pharma industry. We’ve seen layoffs, recalls, outbreaks, criticism of weight-loss drugs—and we still have three-quarters of the year to go….
A company’s ability to pivot and adapt — its agility — is more than just an asset. In today’s dynamic contract manufacturing landscape, it’s a necessity. Agility allows a CDMO…
